Results 61 to 70 of about 748,662 (261)

Efficacy and toxicity of low-doses versus standard-dose enzalutamide in advanced prostate cancer: a real-world study with implications for cancer prevention/interception

BMC Cancer
Background Enzalutamide at standard doses (160 mg/day) is effective in advanced prostate cancer (PCa) but is associated with considerable adverse events (AEs) and high financial costs.
Martino Oliva, Monica Boitano, Alessio Carbone, Irene Maria Briata, Tania Buttiron Webber, Davide Corradengo, Carlo Introini, Matteo Puntoni, Marco Ennas, Federico Germinale, Nicoletta Provinciali, Matteo Clavarezza, Alberto Gozza, Carlotta Defferrari, Mauro D’Amico, Howard L. Parnes, Andrea DeCensi   +16 more
doaj   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

Molecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel   +14 more
wiley   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Pioglitazone and bladder cancer risk: a systematic review and meta‐analysis

Cancer Medicine, 2018
Current evidence about the association between pioglitazone and bladder cancer risk remains conflict. We aimed to assess the risk of bladder cancer associated with the use of pioglitazone and identify modifiers that affect the results.
Huilin Tang, Weilong Shi, Shuangshuang Fu, Tiansheng Wang, Suodi Zhai, Yiqing Song, Jiali Han   +6 more
doaj   +1 more source

Resposta imune humoral de cães à vacina inativada, de cérebro de camundongos lactentes, utilizada nas campanhas anti-rábicas no Brasil Humoral immune response of dogs to the inactivated suckling mouse brain vaccine utilized in anti-rabies campaigns in Brazil

Revista de Saúde Pública, 1997
INTRODUÇÃO: A campanha anti-rábica no Brasil é realizada anualmente utilizando a vacina de cérebro de camundongos lactentes Fuenzalida-Palacios. A resposta imune humoral de cães vacinados durante as campanhas foi analisada objetivando avaliar se os cães ...
Marilene F. Almeida, Elizabeth A. C. Aguiar, Luzia A. F. Martorelli, Douglas Presotto, Marcelo M. Brandão, Octávio A. C. Pereira   +5 more
doaj   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

A unified dose response relationship to predict high dose fractionation response in the lung cancer stereotactic body radiation therapy

Journal of Medical Physics, 2017
Aim: This study is designed to investigate the superiority and applicability of the model among the linear-quadratic (LQ), linear-quadratic-linear (LQ-L) and universal-survival-curve (USC) models by fitting published radiation cell survival data of lung ...
Than S Kehwar, Kashmiri L Chopra, Durg V Rai   +2 more
doaj   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source